ScholarLens Back to search
2005•Unpublished venueRequires access

Metastatic adhesion molecule CD44 variant 6 and the pathobiological behavior of gastric cancer

Anguang He

Open publisher page 0 citations

Abstract

Objective: To investigate the expression of CD44v6 in gastric cancer and to evaluate its prognostic value. Methods:The expression of CD44v6 was analyzed immunohistochemically in gastric cancer by using monoclonal antibody. We investigated the relationship between CD44v6 expression and prognosis in 113 patients with gastric cancer. (Results):CD44v6 expressed in the membrane of cancer cells in 16.7% (5/30) of EGC,25% (4/16) of MGC,and 49.3% (33/67) of AGC(P0.01). CD44v6 was detected in 48.3% (28/58) of patients with lymph node metastasis(Mets) and in 71.4% (5/7) of those with liver metastasis, while only in 19.6% (9/46) of those without any metastasis(P(0.05)). Significantly more cases of intestinal-type gastric cancer had theexpression of CD44v6thandiffuse-typecases(P(0.01)).Conclusion:CD44v6 protein may play an important role in progression and metastatic potential of gastric cancer, and may be a biologic marker of gastric cancer.

About this research paper

What this paper is about

Objective: To investigate the expression of CD44v6 in gastric cancer and to evaluate its prognostic value. Methods:The expression of CD44v6 was analyzed immunohistochemically in gastric cancer by using monoclonal antibody. We investigated the relationship between CD44v6 expression and prognosis in 113 patients with gastric cancer. (Results):CD44v6 expressed in the membrane of cancer cells in 16.7% (5/30) of EGC,25% (4/16) of MGC,and 49.3% (33/67) of AGC(P0.01). CD44v6 was detected in 48.3% (28/58) of patients with lymph node metastasis(Mets) and in 71.4% (5/7) of those with liver metastasis, while only in 19.6% (9/46) of those without any metastasis(P(0.05)). Significantly more cases of intestinal-type gastric cancer had theexpression of CD44v6thandiffuse-typecases(P(0.01)).Conclusion:CD44v6 protein may play an important role in progression and metastatic potential of gastric cancer, and may be a biologic marker of gastric cancer.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To investigate the expression of CD44v6 in gastric cancer and to evaluate its prognostic value. Methods:The expression of CD44v6 was analyzed immunohistochemically in gastric cancer by using monoclonal antibody. We investigated the relationship between CD44v6 expression and prognosis in 113 patients with gastric cancer. (Results):CD44v6 expressed in the membrane of cancer cells in 16.7% (5/30) of EGC,25% (4/16) of MGC,and 49.3% (33/67) of AGC(P0.01). CD44v6 was detected in 48.3% (28/58) of patients with lymph node metastasis(Mets) and in 71.4% (5/7) of those with liver metastasis, while only in 19.6% (9/46) of those without any metastasis(P(0.05)). Significantly more cases of intestinal-type gastric cancer had theexpression of CD44v6thandiffuse-typecases(P(0.01)).Conclusion:CD44v6 protein may play an important role in progression and metastatic potential of gastric cancer, and may be a biologic marker of gastric cancer.

Key concepts: CD44, Cancer, Medicine, Metastasis, Immunohistochemistry, Cancer cell, Monoclonal antibody, Cell adhesion molecule

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Metastatic adhesion molecule CD44 variant 6 and the pathobiological behavior of gastric cancer — Research Paper | ScholarLens